Hormone replacement therapy, previous breast surgery, and a low body mass index may reduce the accuracy of screening mammography, according to a study in the August issue of the British Medical Journal.
Hormone replacement therapy, previous breast surgery, and a low body mass index may reduce the accuracy of screening mammography, according to a study in the August issue of the British Medical Journal.
Age, family history, physical activity levels, smoking, and alcohol consumption did not significantly affect the exam's sensitivity or specificity.
Dr. Emily Banks, deputy director of the cancer research U.K. epidemiology unit at the University of Oxford, and colleagues studied 122,355 women from 50 to 64 years of age. The participants in the U.K.'s Million Women Study had all completed a lifestyle questionnaire and were monitored for 12 months.
The researchers reported an overall sensitivity of 86.6% and specificity of 96.8% for the diagnosis of breast cancer in 726 women.
The following factors had an adverse affect on both sensitivity and specificity:
Women who have these confounding factors also are more likely than other women to have breast cancer diagnosed between screens, Banks said.
While study results indicate that some women may be at a disadvantage in terms of screening mammogram accuracy, the researchers cautioned that it is still the best way to find early stage breast cancers.
They highlighted their results as indicative of the importance of routine screening and of women remaining vigilant between screenings.
For more from the online Diagnostic Imaging archives:
False-positive rate for screening mammography drops
Yearly mammograms prove insufficient for BRCA carriers
MR spectroscopy adds specificity to breast MR
Dutch researchers dismiss HRT link to breast density
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.